| Philip Chadwick, MD | |
|
24800 Se Stark St, Gresham, OR 97030-3378 | |
| (503) 464-9034 | |
| Not Available |
| Full Name | Philip Chadwick |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 24800 Se Stark St, Gresham, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861430738 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD19305 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Philip Chadwick, MD 6312 Sw Capitol Hwy, #502, Portland, OR 97239-1938 Ph: (503) 464-9034 | Philip Chadwick, MD 24800 Se Stark St, Gresham, OR 97030-3378 Ph: (503) 464-9034 |
News Archive
Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC").
The first double-blind, placebo-controlled randomized trial of VEGF gene injections into the heart muscle of patients with coronary artery disease with the intention of spurring growth of new blood vessels showed significant effects on heart wall motion, although blood flow was not significantly better in treated patients, according to a new study in the April 5, 2005, issue of the Journal of the American College of Cardiology.
Three of America's best known voices in the debate about evolution in the teaching of science will meet to discuss the issue on Sunday, April 29, 2007 in Washington, DC.
Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
› Verified 7 days ago
Karen Jeanne O'neill, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 24800 Se Stark St, Gresham, OR 97030 Phone: 503-674-1400 | |
Dr. Kelly Leaf, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 24800 Se Stark St, Emergency Department, Gresham, OR 97030 Phone: 503-674-1122 | |
Nigel M Longland, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 24800 Se Stark St, Gresham, OR 97030 Phone: 503-674-1400 | |
Fredrick R Bradshaw, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 24800 Se Stark St, Gresham, OR 97030 Phone: 503-674-1400 | |
Daniel R Berger, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 24800 Se Stark St, Gresham, OR 97030 Phone: 503-674-1122 | |
Crystal Weis, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 24800 Se Stark St, Gresham, OR 97030 Phone: 503-674-1122 | |
Anthony A Ferroggiaro, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2850 Se Powell Valley Rd, Gresham, OR 97080 Phone: 503-666-5050 |